| Literature DB >> 29385101 |
Ye' Zaw Phyo1,2, João Ribeiro3, Carla Fernandes4,5, Anake Kijjoa6,7, Madalena M M Pinto8,9.
Abstract
Over the last decaEntities:
Keywords: Marfey’s method; absolute configuration; bioactivity; chiral HPLC; marine peptides; stereochemistry
Mesh:
Substances:
Year: 2018 PMID: 29385101 PMCID: PMC6017543 DOI: 10.3390/molecules23020306
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Schematic presentation of the methodologies generally used for determination of the configuration of amino acid residues of marine peptides. HPLC—High Performance Liquid Chromatography; CSP—Chiral Stationary Phase; FDAA—1-Fluoro-2-4-dinitrophenyl-5-d,l-alanine amide; FDLA—1-Fluoro-2-4-dinitrophenyl-5-d,l-leucine amide.
Cyclic peptides from marine cyanobacteria and other bacteria.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Refs. |
|---|---|---|---|---|---|
| Tetrapeptide ( | Bacterium | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity toward the leukemia cell-line K-562 | [ | |
| Anabaenopeptins NZ825, NZ841, NZ857 ( | Cyanobacterium | Marfey’s method (FDAA) combined with HPLC | No inhibition of serine proteases | [ | |
| Aurilides B ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex 3126 (D) (4.6 × 250 mm); | Cytotoxicity against NCl-H460 and neuro-2a mouse neuroblastoma cell lines | [ | |
| Marfey’s method (FDAA) combined with HPLC | |||||
| Urukthapelstatin A ( | Marine Derived | Marfey’s method (FDAA) combined with HPLC | Growth inhibition of human lung cancer A549 cells, cytotoxicity against a human cancer cell line panel | [ | |
| Ligand Exchange Type CSPSumichiral OA-5000 column (4.6 × 150 mm) | |||||
| Pompanopeptins A ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex 3126 | [ | ||
| Marfey’s method (FDLA) combined with HPLC-MS | |||||
| Marfey’s method (FDLA) combined with HPLC-MS | |||||
| Marthiapeptide A ( | Deep sea-derived | Ligand Exchange Type CSP; MCIGELCR10W (4.6 × 150 mm); | Antibacterial and cytotoxic activities | [ | |
| Marfey’s method (FDAA) combined with HPLC | |||||
| Nocardiamides A ( | Marine-derived Actinomycete | Marfey’s method (FDAA or FDLA) combined with HPLC; Conditions not described | Antimicrobial activity and no cytotoxicity against HCT-116 cell line | [ | |
| Ligand Exchange Type CSP; MCIGELCRS10W, (4.6 × 250 mm); | |||||
| Destomides B–D ( | Deep sea-derived | Marfey’s method (FDAA) combined with HPLC | [ | ||
| Ligand Exchange Type CSP; MCIGELCRS10W column, 3 µm (4.6 × 50 mm); | |||||
| Janadolide ( | Cyanobacterium | Ligand Exchange Type CSP; Diacel CHIRALPAK (MA+) (4.6 × 50 mm); | Antitrypanosomal activity | [ | |
| Marfey’s method (FDAA) combined with HPLC | |||||
| Wewakazole B ( | Cyanobacterium | Macrocyclic Antibiotic type CSP | Cytotoxicity against MCF7 and human 460 lung cancer cell lines | [ | |
| Ligand Exchange type CSP; Sumichiral OA-5000 (4.6 × 150 mm); |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; ESI—Electrospray Ionization; LC—Liquid Chromatography; MS—Mass spectrometry; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; TEAP—Triethylammonium phosphate; ACN—Acetonitrile; CPA—Carboxypeptidase A; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; IPA—Isopropyl alcohol; FDLA—1-fluoro-2-4-dinitrophenyl-5-d,l-leucine amide; NaOAc—Sodium acetate; NH4OAc—Ammonium acetate.
Figure 2Structure of cyclic peptides 1–16, isolated from marine cyanobacteria and other bacteria, whose stereochemistry determination of their amino acids was performed by Marfey’s method (compounds 1–4) and by a combination of both Marfey’s method and chiral HPLC (compounds 5–16).
Figure 3Structure of wewakazole B (17) isolated from a marine cyanobacteria.
Cyclic depsipeptides from marine cyanobacteria and other bacteria.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Refs. |
|---|---|---|---|---|---|
| Malevamides | Cyanobacterium | Ligand Exchange Type CSP; Chirex (D) Penicillamine, Phenomenex 00G-3126E0 (4.6 × 250 mm) | Inactive against P-388, A-549 and HT-29 cancer cells | [ | |
| Lyngbyapeptin B ( | Cyanobacterium | Ligand Exchange Type CSP; Chirex (D) Penicillamine, Phenomenex 00G-3126E0 (4.6 × 250 mm) | Cytotoxicity against KB and LoVo cells | [ | |
| Tasipeptins A ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex Phase 3126 (D) (4.6 × 250 mm) | Cytotoxicity toward KB cells | [ | |
| Wewakamide A ( | Cyanobacteria | Ligand Exchange Type CSP; Phenomenex Chirex 3126 (D) (4.6 × 250 mm); | Brine shrimp toxicity | [ | |
| Cocosamide A ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex (D), Penicillamine, 5 µm (4.6 × 250 mm) | Cytotoxicity against MCF-7 (breast cancer) and HT-29 (colon cancer) cells | [ | |
| Dudawalamides A–D | Cyanobacterium | Ligand Exchange Type CSP; Chirex Phase 3126 (D) 5 µm (4.6 × 250 mm); | Antiparasitic activity | [ | |
| Pitipeptolides | Cyanobacterium | Ligand Exchange Type CSP; Chiralpak MA (+) (4.6 × 50 mm); | Cytotoxic, antimycobacterial and elastase inhibitory activities | [ | |
| Kohamamides A–C | Cyanobacterium | Ligand Exchange Type CSP; Chiralpak MA (+) (4.6 × 250 mm); | No growth inhibition against HeLa and HL60 cells | [ | |
| Marformycins A–F ( | Deep sea-derived | Ligand Exchange Type CSP; MCIGELCRS10W (4.6 × 50 mm); | Anti-infective activity against | [ | |
| Pitiprolamide ( | Cyanobacterium | Macrocyclic Antibiotic Type CSP; Chirobiotic TAG (4.6 × 250 mm); | Cytotoxicity against CT116 and MCF7 cancer cell lines and antibacterial activity | [ | |
| Palau’amide ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex Phase 3126 (D) (4.6 × 250 mm) | Cytotoxicity against KB cell line | [ | |
| Pitipeptolides C–F ( | Cyanobacterium | Macrocyclic Antibiotic Type CSP; Chirobiotic TAG (4.6 × 250 mm); | [ | ||
| Ulongapeptin ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex Phase 3126 (D), 4.6 × 250 mm | Cytotoxicity against KB cells | [ | |
| Marfey’s method (FDLA) combined with HPLC | |||||
| 2-hydroxy-3-methylvaleric acid | Ligand Exchange Type CSP; CHIRALPAK MA (+) (4.6 × 50 mm); | ||||
| Largamides A–H ( | Cyanobacterium | Marfey’s method (FDLA) combined with HPLC | [ | ||
| Ligand Exchange Type CSP; Phenomenex Chirex 3126 (D) (4.6 × 150 mm); | |||||
| Trungapeptins | Cyanobacterium | Marfey’s method (FDLA) combined with HPLC. Alltech Econosil C18; | Brine shrimp toxicity and ichthyotoxicity | [ | |
| Phenyllactic acid ( | Ligand Exchange Type CSP; CHIRALPAK MA (+) (4.6 × 50 mm); | ||||
| Carriebowmide ( | Cyanbacterium | Ligand Exchange Type CSP; Phenomenex, Chirex (D) Penicillamine, 5μm (4.6 × 250 mm) | Lipophilic extract reduced feeding on agar food pellets | [ | |
| Ligand Exchange Type CSP; Chiralpak MA (+) (4.6 × 250 mm); | |||||
| Ligand Exchange Type CSP; Phenomenex, Chirex (D) Penicillamine, 5 μm (4.6 × 250 mm); | |||||
| (2 | Marfey’s method (FDAA) combined with HPLC | ||||
| Symplocamide A ( | Cyanobacterium | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity and antimicrobial | [ | |
| Kempopeptins A ( | Cyanobacterium | Marfey’s method (FDLA) combined with HPLC | [ | ||
| Ligand Exchange Type CSP; Phenomenex Chirex Phase 3126 | |||||
| Tiglicamides A–C ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex, Chirex 3126, 5 μm (4.6 × 250 mm); Mobile Phase: 2 mM CuSO4 | Porcine pancreatic elastase inhibition | [ | |
| Marfey’s method (FDLA) combined with HPLC | |||||
| Hantupeptin B ( | Cyanobacterium | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity against MOLT-4 (leukemic) and MCF-7 (breast cancer) cell lines | [ | |
| Ligand Exchange Type CSP; Chiralpak MA (+) (4.6 × 500 mm) | |||||
| Palmyramide A ( | Cyanobacterium | Marfey’s method (FDAA) combined with HPLC/MS on a Merck LiChrospher 100 RP-18 (4.0 × 125 mm) | Sodium channel blocking activity in neuro-2a cells and cytotoxic activity in H-460 (human lung carcinoma) cells | [ | |
| Ligand Exchange Type CSP; Phenomenex Chirex 3126 (4.6 × 250 mm); Conditions not described | |||||
| Veraguamides A–G ( | Cyanobacterium | Macrocyclic Antibiotic Type CSP; Chirobiotic TAG (4.6 × 250 mm); | Cytotoxic activity against HT29 (colorectal adenocarcinoma) and HeLa (cervical carcinoma) cell lines | [ | |
| Marfey’s method (FDAA) combined with HPLC-MS | |||||
| Porpoisamides A ( | Cyanobacterium | Ligand Exchange Type CSP; Phenomenex Chirex 3126 (4.6 × 250 mm); | Cytotoxicity against HCT 116 (colorectal carcinoma) and U2OS (osteosarcoma) cells | [ | |
| Ligand Exchange Type CSP; Chiralpak MA (+) (4.6 × 50 mm); | |||||
| (2 | Marfey’s method (FDAA) combined with HPLC | ||||
| Ligand Exchange Type CSP; CHIRALPAK MA (+) (4.6 × 50 mm); | |||||
| Companeramides A ( | Cyanobacterial assemblage collected from Coiba National Park, Panama | Marfey’s method (FDAA) combined with HPLC | Antiplasmodial activity against | [ | |
| Ligand Exchange Type CSP; Phenomenex Chirex 3126 (D) (4.6 × 250 mm); | |||||
| Piperazimycins A–C ( | Fermentation broth of a | ( | Marfey’s method (FDAA) combined with HPLC | [ | |
| Grassypeptolides D ( | Red sea cyanobacterium | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity against HeLa and mouse neuro-2a blastoma cells | [ | |
| Marfey’s method (FDAA) combined with HPLC | |||||
| Fijimycins A–C ( | Fermentation broth of | Marfey’s method (FDAA) combined with HPLC | Antibacterial activity against three MRSA strains of | [ | |
| Itralamides A ( | Cyanobacterium | Marfey’s method (FDLA) combined with HPLC | [ | ||
| Marfey’s method (FDLA) combined with HPLC | |||||
| Marfey’s method (FDLA) combined with HPLC-PDA | |||||
| Viequeamide A ( | Marine button cyanobacterium | Marfey’s method (FDLA) combined with HPLC | Highly toxic to H460 (human lung cancer) cells | [ | |
| Ngercheumicin | Photobacterium related to | Marfey’s method (FDLA) combined with HPLC | [ |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; LC—Liquid Chromatography; MS—Mass Spectrometry; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; TEAP—Triethylammonium phosphate; ACN—Acetonitrile; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; IPA—Isopropyl alcohol; FDLA—1-Fluoro-2-4-dinitrophenyl-5-d,l-leucine amide; NaOAc—Sodium acetate; NH4OAc—Ammonium acetate.
Figure 4Structure of cyclic depsipeptides 18–46, isolated from marine cyanobacteria and other bacteria, whose stereochemistry of their amino acids was determined only by chiral HPLC.
Figure 5Structure of cyclic depsipeptides 47–78, isolated from marine cyanobacteria and other bacteria, whose stereochemistry of their amino acids was determined by a combination of Marfey’s method and chiral HPLC.
Figure 6Structure of cyclic depsipeptides 79–94, isolated from marine cyanobacteria and other bacteria, whose stereochemistry of their amino acids was determined by Marfey’s method.
Figure 7Structure of lipopeptides 95–98, isolated from marine cyanobacteria.
Lipopeptides from marine cyanobacteria.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Antillatoxin B ( | Cyanobacterium | Marfey’s method (FDAA) combined with HPLC Waters Nova-Pak C18 (3.9 × 150 mm), | Sodium channel-activating and ichthyotoxic activities | [ | |
| Lobocyclami-des A–C ( | Cyanobacterium | Ligand Exchange Type CSP Chirex 3126 ( | Antifungal activity against a panel of | [ | |
| Marfey’s method (FDAA) combined with HPLCC18 column (4.8 × 250 mm); |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; ACN—Acetonitrile; TFA—Trifluoracetic acid.
Figure 8Structure of cyclic peptides 99–112, isolated from marine-derived fungi.
Cyclic peptides from marine-derived fungi.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Cyclo-( | Marine mangrove-derived fungi | 4-OH- | Marfey’s method (FDAA) combined with LC/MS | Inhibition against four crop-threatening fungi | [ |
| Scytalidamides A ( | Marine Fungus of the genus | Marfey’s method (FDLA) combined with HPLC | Cytotoxicity against HCT-116 and NCI 60 cell lines | [ | |
| Clonostachysins A ( | Marine sponge-derived fungus | Marfey’s method (FDLA) combined with LC-ESI MS/MS; Conditions not described | Inhibitory effect on dinoflagellate | [ | |
| Asperterrestide A ( | Marine-derived fungus | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity against U937 and MOLT4 human carcinoma cell lines and inhibitory effects on influenza virus | [ | |
| Ligand Exchange Type CSP; MCI GELCRS 10 W (4.6 × 50 mm); | |||||
| Sclerotides A ( | Marine-derived fungus, | Crown Ether CSP; Crownpak CR (+); | [ | ||
| Cordyheptapeptides C–E ( | Marine-derived fungus | Crown Ether Chiral CSP; Crownpak CR (+) | [ | ||
| Similanamide ( | Marine sponge-associated fungus | Macrocyclic Antibiotic Type CSP; Chirobiotic T, 5 μm (4.6 × 150 mm); | Cytotoxicity against | [ | |
| Sartoryglabramide A ( | Marine sponge-associated fungus | Macrocyclic Antibiotic Type CSP; Chirobiotic T, 5 μm (4.6 × 150 mm); | Neither antibacterial nor antifungal activity | [ |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; ACN—Acetonitrile; TFA—Trifluoracetic acid; MeOH—Methanol; FDLA—1-fluoro-2-4-dinitrophenyl-5-d,l-leucine amide.
Figure 9Structure of cyclic depsipeptides 113–131, isolated from marine-derived fungi.
Cyclic depsipeptides from marine-derived fungi.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Exumolides A ( | Fungus of the genus | Marfey’s method (FDAA) combined with HPLC | Antimicroalgal activity against unicellular chlorophyte | [ | |
| Guangomide A ( | Sponge-derived fungus | Marfey’s method (FDAA) combined with HPLC | Antibacterial activity against | [ | |
| Destruxin E chlorohydrin ( | Marine-derived fungus | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity in NCI’s 60 cell line panel | [ | |
| Zygosporamide ( | Marine-derived fungus | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity in RXF 393 and SF-268 cancer cell lines | [ | |
| Petriellin A ( | Coprophilous fungus | Marfey’s method (FDAA) combined with HPLC | Antifungal activity | [ | |
| Alternaramide ( | Marine derived fungus | Marfey’s method (FDAA) combined with HPLC | Antibacterial activity against | [ | |
| Petrosifungins A ( | Marfey’s method (FDAA) combined with HPLC | Not described | [ | ||
| Oryzamides A–E ( | Sponge-Derived fungus | Marfey’s method (FDLA) combined with UHPLC | No cytotoxicity, antibacterial, antiparasitic, and NF- | [ | |
| Spicellamide A ( | Marine-derived fungus | Marfey’s method (FDAA) combined with HPLC | [ | ||
| Ligand Exchange Type CSP; Phenomenex Chirex 3126 | |||||
| Depsipeptides 1962A ( | Endophytic fungus | Crown Ether CSP; Crownpak CR (+) column (0.4 × 150 mm), | [ |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; ACN—Acetonitrile; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; FDLA—1-Fluoro-2-4-dinitrophenyl-5-d,l-leucine amide; NaOAc—Sodium acetate; NH4OAc—Ammonium acetate.
Figure 10Structure of cyclic peptides 132–151, isolated from marine sponges.
Figure 11Structure of cyclic peptides 152–164, isolated from marine sponges.
Cyclic peptides from marine sponges.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Haliclamide ( | Vanuatu marine sponge | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity against NSCLC-N6 carcinoma cell line | [ | |
| Microsclerodermins J ( | Deep water sponge | Marfey’s method (FDAA) combined with HPLC | Activity against opportunistic pathogenenic fungi | [ | |
| Euryjanicins E–G ( | The Caribbean Sponge | Marfey’s method (FDAA) combined with HPLC | No significant activity cytotoxicity against the National Cancer Institute 60 tumor cell line panel | [ | |
| Chujamide A ( | Marine sponge | Marfey’s method (FDAA) combined with HPLC | Weak cytotoxicity against A549 and K562 cell lines | [ | |
| Kapakahines A–D ( | Marine Sponge | Marfey’s method (FDAA) combined with HPLC | [ | ||
| Koshikamide B ( | Marine sponge | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity against P388 and HCT-116 tumor cell lines | [ | |
| Perthamides C ( | Solomon Lithistid sponge | Marfey’s method (FDAA) combined with HPLC/MS Proteo C18 column (1.8 × 25 mm) | Anti-inflammatory activity | [ | |
| Perthamides E ( | Polar extracts of the sponge | Marfey’s method (FDAA) combined with HPLC | [ | ||
| Stylisins 1 ( | Jamaican sponge | Marfey’s method (FDAA) combined with HPLC | No antimicrobial, antimalarial, anticancer, anti-HIV-1, anti-Mtb and anti-inflammatory activities | [ | |
| Carteritins A ( | Marine sponge | Marfey’s method (FDAA) combined with HPLC | [ | ||
| Stylissatins B–D ( | Marine sponge | Marfey’s method (FDAA) combined with HPLC | [ | ||
| Callyaerin G ( | Indonesian sponge | Marfey’s method (FDAA) combined with HPLC/MS; Conditions not described | Cytotoxicity against L5178Y, Hela, and PC12 | [ | |
| Reniochalistatins A–E ( | Marine sponge | Ligand Exchange Type CSP; MCI GELCRS 10 W (4.6 × 50 mm); | [ | ||
| Marfey’s method (FDAA) combined with HPLC YMC-Park Pro C18, 5 µm (4.6 × 250 mm) | |||||
| Phakellistatins 15–18 ( | South china sea sponge | Ligand-exchange type CSP; Chirex 3126 ( | [ |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; LC—Liquid Chromatography; MS—Mass spectrometry; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; TEAP—Triethylammonium phosphate; ACN—Acetonitrile; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; IPA—Isopropyl alcohol; NaOAc—Sodium acetate; NH4OAc—Ammonium acetate.
Figure 12Structure of cyclic depsipeptides 165–179, isolated from marine sponges.
Figure 13Structure of cyclic depsipeptides 180–195, isolated from marine sponges.
Cyclic depsipeptides from marine sponges.
| Peptide | Source | aa Composition | Chromatographic conditions | Biological activities | Ref. |
|---|---|---|---|---|---|
| Callipeltins B ( | Marfey’s method (FDAA) combined with HPLC; Column not described; MP: TEAP (50 nM, pH 3.0):ACN 90–50% TEAP | Cytotoxicity | [ | ||
| Halipeptiins A ( | Marfey’s method (FDAA) combined with HPLC | [ | |||
| Phoriospongin A ( | Marfey’s method (FDAA) combined with HPLC | Nematocidal activity against the parasite | [ | ||
| Mirabamides A–D ( | Marfey’s method (FDAA) combined with HPLC | [ | |||
| Neamphamides B ( | Marfey’s method (FDAA) combined with HPLC | Growth inhibition of human cell lines: A549, HeLa, LNCaP, PC3, and NFF | [ | ||
| Pipecolidepsins A ( | Marfey’s method (FDAA) combined with HPLC | Cytotoxicity against three human tumor cell lines (A-549, HT-29, and MDA-MB-231) | [ | ||
| Stellatolide A ( | Marfey’s method (FDAA) combined with HPLC Hewlett-Packard Hypersil BDS-C18, 4 µm (4.0 × 100 mm); MP: H2O (0.1% TFA):ACN (90:10 to 50:50 | In in vitro antiproliferative activity | [ | ||
| Cyclolithistide A ( | nor- | Marfey’s method (FDAA) combined with HPLC | Antifungal activity against | [ | |
| Nagahamide A ( | Marfey’s method (FDAA) combined with HPLC | Antibacterial activity | [ | ||
| Theopapuamides B ( | Marfey’s method (FDAA) combined with HPLC/MS | [ | |||
| Ligand Exchange Type CSP Phenomenex column, Chirex Phase 3126 (D) (4.6 × 150 mm); MP: 1 mM CuSO4:ACN (95:5 | |||||
| Theopapuamide ( | Lithistid sponge | Ligand Exchange Type CSP Chirex Phase 3126 (D), 5 µm | Cytotoxicity against CEM-TART and HCT-cell lines | [ | |
| Marfey’s method (FDAA) combined with HPLCPhenomenex C18, 5 µm (4.6 × 250 mm); MP: 10–50% ACN in H2O (0.05% TFA); Flow rate: 1.0 mL/min; UV detection at 340 nm | |||||
| Mutremdamide A ( | Marfey’s method (FDAA) combined with HPLC | [ | |||
| Marfey’s method (FDAA) combined with HPLC | |||||
| Chiral HPLC (column not described); MP: 1 mM CuSO4:ACN (95:5 |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; LC—Liquid Chromatography; MS—Mass spectrometry; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; TEAP—Triethylammonium phosphate; ACN—Acetonitrile; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; NaOAc—Sodium acetate; NH4OAc—Ammonium acetate.
Figure 14Structure of cyclic lipopeptides 196–198, isolated from marine sponges.
Lipopeptides from marine sponge.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activity | Ref. |
|---|---|---|---|---|---|
| Sulfolipo-discamides A–C | Sponge | Marfey’s method (FDAA) combined with HPLC Cosmosil C18-MSII column (4.6 × 250 mm); MP: 100 mM NaClO4 in 60% ACN | [ |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; ACN—Acetonitrile.
Figure 15Structure of cyclic peptides 199–206, isolated from marine invertebrates and marine algae.
Cyclic peptides from marine invertebrates and algae.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Didomolamides A ( | Ascidian | Marfey’s method (FDAA) combined with HPLC; MP: 50 mM (TEAP) buffer pH 3: ACN (9:1 to 1:1 | Cytotoxicity against A549, HT29 MEL28 tumor cell lines | [ | |
| Mollamides B ( | Tunicate | Marfey’s method (FDAA) combined with HPLC; MP: 50 mM TEAP, pH 3.0: ACN (90:10 to 60:40 | [ | ||
| Antatollamides A ( | Ascidian | Marfey’s method (FDLA) combined with HPLC/MSHypersil Gold C18 column, 1.9 µm (2.1 × 50 mm); MP: H2O 0.1%; HCOOH:ACN (85:15 to 55:45 | [ | ||
| Sanguinamide A ( | Marfey’s method (FDLA) combined with HPLC Agilent Zorbax SB-Aq C18 column, 5 µm (4.6 × 250 mm) | Antifungal activity | [ | ||
| Gamakamide E ( | Oysters | Marfey’s method (FDLA) combined with HPLC | No growth inhibition abilities | [ |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; ACN—Acetonitrile; TEAP—Triethylammonium phosphate; FDLA—1-Fluoro-2-4-dinitrophenyl-5-d,l-leucine amide; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; NH4OAc—Ammonium acetate.
Figure 16Structure of cyclic depsipeptides 207–217, isolated from marine invertebrates and marine algae.
Cyclic depsipeptides from marine invertebrates and algae.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Kahalalides A–F ( | Mollusk | Marfey’s method (FDLA) combined with HPLC | [ | ||
| Ascidian of the family Didemni-dae | Marfey’s method (FDAA) combined with HPLC | [ | |||
| KahalalidesP | Green alga | Marfey’s method (FDAA) combined with HPLC COSMOSIL 5C18-AR-II (4.6 × 250 mm); MP: 0.1 M NH4OAc pH 3 or 90% aq ACN | No antimicrobial and no hemolytic activities | [ | |
| Kahalalide O ( | Mollusk | Ligand Exchange Type CSP Chirex (D) Penicillamine Column (4.6 × 250 mm); MP: 1.9 mM CuSO4 in ACN:H2O (5:95) or 2.0 mM CuSO4 in H2O; UV detection at 254 nm | No growth inhibition of P-388, A549, HT29 and MEL28 cancer cell lines | [ | |
| Marfey’s method (FDAA) combined with HPLC |
aa—Amino acid; FDAA—1-Fluoro-2-4-dinitrophenyl-5-l-alanine amide; HPLC—High Performance Liquid Chromatography; MP—Mobile Phase; ACN—Acetonitrile; FDLA—1-fluoro-2-4-dinitrophenyl-5-d,l-leucine amide; TFA—Trifluoracetic acid; MeOH—Methanol; TEA—Triethylamine; NH4OAc—Ammonium acetate.
Lipopeptides from marine invertebrates and algae.
| Peptide | Source | aa Composition | Chromatographic Conditions | Biological Activities | Ref. |
|---|---|---|---|---|---|
| Eudistomides A ( | Ascidian | Ligand Exchange Type CSP | No activity reported | [ | |
| Mebamamides A ( | Green algae | Ligand Exchange Type CSP | No growth inhibitory activity against HeLa and HL60 cell lines | [ |
aa—Amino acid; MP—Mobile Phase; ACN—Acetonitrile.
Figure 17Structure of lipopeptides 218–221, isolated from marine invertebrates and marine algae.
Figure 18Chromatograms of enantiomeric mixture of dl-Ala (A), dl-pipecolic acid (B), and dl-Val (C). Column, Chirobiotic T; Mobile phase, MeOH:H2O:acetic acid (70:30:0.02 v/v/v); Flow rate, 1.0 mL/min; UV detection, 210 nm.
Figure 19Chromatograms of enantiomeric mixture of dl-Ala (a), l-Ala (b), and d-Ala (c). Column, Chirobiotic T; Mobile phase, MeOH:H2O:acetic acid (70:30:0.02 v/v/v); Flow rate, 1.0 mL/min; UV detection, 210 nm.
Chiral HPLC analysis of the acidic hydrolysates of 110, 111 and 112 by co-injection with amino acids standards.
| Retention Time (min) | Retention Time (min) | ||
|---|---|---|---|
| 5.20 | 14.67 | ||
| 4.51 | Acidic hydrolysate of | 6.59, 7.20, 8.09, 8.83, 9.67, 10.57, 14.69 | |
| 6.60 | Acidic hydrolysate of | 6.61, 7.31, 8.30, 8.10, 8.84, 9.70, 10.50, 14.95 | |
| 8.32 | Acidic hydrolysate of | 6.59, 7.19, 8.04, 8.81, 9.37, 9.70, 10.50, 14.90 | |
| 7.16 | Acidic hydrolysate of | 6.60, 6.76, 7.26, 8.04, 8.83, 9.67, 10.54, 15.02 | |
| 9.36 | Acidic hydrolysate of | 6.58, 7.20, 8.09, 8.64, 8.84, 9.77, 10.64, 14.64 | |
| 6.78 | Acidic hydrolysate of | 6.59, 7.20, 8.09, 8.83, 9.67, 10.57, 14.69 | |
| 9.67 | Acidic hydrolysate of | 1.91, 2.55, 2.86, 3.49, 3.89, 6.79 | |
| 8.09 | Acidic hydrolysate of | 1.87, 2.50, 2.89, 3.68, 5.01, 6.82 | |
| 3.81 | Acidic hydrolysate of | 1.96, 2.60, 2.96, 3.52, 3,92, 6.70, 21.09 | |
| 5.00 | Acidic hydrolysate of | 1.93, 3.07, 3.80, 4.29, 4.60, 6.62 | |
| 6.72 | Acidic hydrolysate of | 1.90, 3.10, 3.78, 4.39, 5.04, 6.70 | |
| 20.10 | Acidic hydrolysate of | 2.04, 3.02, 3.72, 4.30, 4.60, 6.66, 19.40 | |
| 8.68 | Acidic hydrolysate of | 1.93, 2.99, 3.70, 4.29, 4.60, 5.07, 6.33 |
Column, Chirobiotic T; Mobile phase, MeOH:H2O (80:20 v/v) (A) or MeOH:H2O:acetic acid (70:30:0.02 v/v/v) (B); Flow rate, 1.0 mL/min (A) or 0.5 mL/min (B); UV detection, 210 nm.
Figure 20Distribution of the reported studies concerning the determination of the stereochemistry of marine peptides according to the methods used.
Figure 21Distribution of the studies concerning the determination of the stereochemistry of marine peptides according to the method used before (A) and after 2007 (B).